fifty-five group iii evaluable patients ( pts ) less than 15 years of age with tumor size greater than 5 cm in diameter , without high-risk features of cns involvement , and 15 group iv rms pts were randomized to receive vac as primary chemotherapy ( ct ) : vcr , 1.5 mg/m2 intravenously ( iv ) days 1 and 8 ;
C0035412
rms
C0042679
vcr